Denali Therapeutics Statistics

Total Valuation

DNLI has a market cap or net worth of $3.93 billion. The enterprise value is $2.63 billion.

Market Cap	3.93B
Enterprise Value	2.63B

Important Dates

The next estimated earnings date is Tuesday, November 5, 2024, after market close.

Earnings Date	Nov 5, 2024
Ex-Dividend Date	n/a

Share Statistics

DNLI has 143.17 million shares outstanding. The number of shares has increased by 12.10% in one year.

Shares Outstanding	143.17M
Shares Change (YoY)	+12.10%
Shares Change (QoQ)	+13.00%
Owned by Insiders (%)	4.65%
Owned by Institutions (%)	90.39%
Float	123.76M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	160.42
PB Ratio	2.83
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2,079.29
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 12.46, with a Debt / Equity ratio of 0.04.

Current Ratio	12.46
Quick Ratio	12.04
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -32.61% and return on invested capital (ROIC) is -23.11%.

Return on Equity (ROE)	-32.61%
Return on Assets (ROA)	-22.04%
Return on Capital (ROIC)	-23.11%
Revenue Per Employee	$2,847
Profits Per Employee	-$943,043
Employee Count	445
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

In the past 12 months, DNLI has paid $30,000 in taxes.

Income Tax	30,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +50.93% in the last 52 weeks. The beta is 1.38, so DNLI's price volatility has been higher than the market average.

Beta (5Y)	1.38
52-Week Price Change	+50.93%
50-Day Moving Average	27.24
200-Day Moving Average	21.68
Relative Strength Index (RSI)	51.64
Average Volume (20 Days)	656,688

Short Selling Information

The latest short interest is 7.73 million, so 5.40% of the outstanding shares have been sold short.

Short Interest	7.73M
Short Previous Month	7.74M
Short % of Shares Out	5.40%
Short % of Float	6.25%
Short Ratio (days to cover)	8.86

Income Statement

In the last 12 months, DNLI had revenue of $1.27 million and -$419.65 million in losses. Loss per share was -$2.83.

Revenue	1.27M
Gross Profit	-421.34M
Operating Income	-495.21M
Pretax Income	-419.62M
Net Income	-419.65M
EBITDA	-494.61M
EBIT	-495.21M
Loss Per Share	-$2.83

Full Income Statement

Balance Sheet

The company has $896.04 million in cash and $48.75 million in debt, giving a net cash position of $1.30 billion or $9.07 per share.

Cash & Cash Equivalents	896.04M
Total Debt	48.75M
Net Cash	1.30B
Net Cash Per Share	$9.07
Equity (Book Value)	1.39B
Book Value Per Share	9.69
Working Capital	853.85M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$390.86 million and capital expenditures -$11.24 million, giving a free cash flow of -$402.10 million.

Operating Cash Flow	-390.86M
Capital Expenditures	-11.24M
Free Cash Flow	-402.10M
FCF Per Share	-$2.81

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-39,085.40%
Pretax Margin	-33,119.49%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-31,736.31%

Dividends & Yields

DNLI does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.10%
Shareholder Yield	-12.10%
Earnings Yield	-10.67%
FCF Yield	-10.22%

Dividend Details

Analyst Forecast

The average price target for DNLI is $38.22, which is 39.13% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$38.22
Price Target Difference	39.13%
Analyst Consensus	Strong Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	16.76%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

DNLI has an Altman Z-Score of 13.39 and a Piotroski F-Score of 1.

Altman Z-Score	13.39
Piotroski F-Score	1